Boston Cell Standards has established the Consortium for Analytic Standardization in Immunohistochemistry. The organization is led by an international panel of pathologists and scientists focused on improving patient immunohistochemistry test accuracy and reproducibility.
Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.
